U.S., May 19 -- ClinicalTrials.gov registry received information related to the study (NCT07594067) titled 'TCR1188-ABC Cells in KRAS-mutated Cancers' on May 11.
Brief Summary: This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma, cholangiocarcinoma, colorectal cancer, or non-small cell lung cancer (NSCLC) will be targeted for participation. Up to 4 total dose levels will be evaluated using a 3+3 dose escalation design.
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Cholangiocarcinoma
Colorectal Canc...